Harnessing the Power of the Immune System
Our industry-leading cell therapy technology uses the power of a person's own immune system to target and attack their tumors. This is accomplished through the use of genetically modified T cells that can increase the number of tumor-specific T cells and strengthen the body’s ability to kill certain types of cancer cells.
We believe cell therapy has the power to transform cancer care, so we’re pursuing all potential avenues to help bring it to those who need it.
Our T Cell Therapy Process in Action
COLLECT patient's white blood cells
Isolate and activate T cells
Engineer T cells with CAR or TCR gene
Grow and expand number of T cells
Infuse same patient with engineered T cells
Cell Therapy Platforms
We are developing engineered cell therapies that express either a chimeric antigen receptor (CAR) or a T cell receptor (TCR), depending on the type of cancer. Our dual platform has the potential to address both hematological cancers and solid tumors.
Chimeric Antigen Receptor (CAR) Explained
CARs are modified proteins composed of two distinct functional components. The first consists of an antibody fragment or target binding domain that allows CARs to recognize targets that are present on the surface of cancer cells. The second provides signals that are designed to rapidly and powerfully activate the T cell to attack cancer cells. We are developing multiple CAR product candidates, including axicabtagene ciloleucel and KTE-X19, while continuing to innovate the next generation of CAR-engineered T cells.
T Cell Receptor (TCR) Explained
TCRs are proteins that allow T cells to identify and destroy tumors by recognizing specific fragments of cancer cells displayed on their surface. Following leukapheresis, T cells are genetically modified with a TCR gene, and the engineered TCR T cells have the ability to recognize and attack various types of tumor cells. Kite, in collaboration with its partners, is currently advancing several TCR programs that target cancer-specific proteins, such as cancer/testis antigens, viral antigens, and neoantigens.
TCR therapy is investigational, and its safety and efficacy have not been established.